tiprankstipranks
Trending News
More News >
Vyome Holdings (HIND)
NASDAQ:HIND
US Market
Advertisement

Vyome Holdings (HIND) Earnings Dates, Call Summary & Reports

Compare
616 Followers

Earnings Data

Report Date
Period Ending
Consensus EPS Forecast
Last Year’s EPS
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q
Earnings Call Date:|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted several positive achievements, such as revenue growth, cost reductions, improved profit margins, and strategic agreements aimed at enhancing shareholder value. However, it also acknowledged challenges, such as the contraction in revenue over the nine-month period and competition from GLP-1 pharmaceuticals. Overall, the positive aspects slightly outweigh the negative trends.
Company Guidance
During the third quarter of 2024, ReShape Lifesciences demonstrated significant financial and operational improvements. Revenue increased by 16.6% compared to the previous quarter and 6.4% year-over-year, marking the third consecutive quarter of growth. The company achieved a gross profit margin of 62.8% for the quarter, with a cumulative margin of 60.3% for the first nine months. Operating expenses were reduced by over 40% compared to the same period last year, and total operating costs for the first nine months were down by 41%. ReShape also reported a non-GAAP adjusted EBITDA of $1.6 million for the quarter, an improvement from a $2.9 million loss in the prior year. In addition, the company secured a supplementary NIH grant of approximately $241,000, bringing total NIH funding to $1.15 million. The company also received approval for its Lap-Band 2.0 FLEX from Health Canada, further expanding its market opportunities.
Revenue Growth
Revenue increased by 16.6% in the third quarter over the second quarter and 6.4% over the third quarter of last year.
Cost Reduction Achievements
Achieved over 40% reduction in operating expenses for the first 9 months of the year compared to last year.
Gross Profit Margin Improvement
Gross profit margin increased to 62.8% for the quarter and 60.3% for the first 9 months.
Lap-Band 2.0 FLEX Approval
Received approval for the Lap-Band 2.0 FLEX from Health Canada, supporting global regulatory efforts.
NIH Grant Award
Awarded a $241,000 supplementary grant from NIH, bringing total awards to $1.15 million.
Merger and Asset Sale Agreements
Coordinated merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad, expected to maximize stockholder value.

Vyome Holdings (HIND) Earnings, Revenues Date & History

Currently, no data available
Please return soon. This page is being updated.
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

HIND Earnings History

Currently, no data available
Please return soon. This page is being updated.

FAQ

When does Vyome Holdings (HIND) report earnings?
Currently, no data Available
What is Vyome Holdings (HIND) earnings time?
Currently, no data Available
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
    What companies are reporting earnings today?
    You can see a list of the companies which are reporting today on TipRanks earnings calendar.
      What is HIND EPS forecast?
      Currently, no data Available
      What am I Missing?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis